RxDoctor Payments Data

Elizabeth Skinner, MD

Gynecologic Oncology · Winston Salem, NCNPI 1558314369

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Merck at 31.8% of the total. That places this record below the midpoint for gynecologic oncology clinicians in NC, where the typical reported total is $1,376.

$346in general payments, 2019–2025

Across 9 payments — averaging $38.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$110
  • Tesaro, Inc.$85
  • Intuitive Surgical$42
  • GSK$32
  • AstraZeneca$25
  • Genmab U.S., Inc.$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$346 in reported general payments places this provider in the 20th percentile of 52 gynecologic oncology providers in North Carolina.

See all gynecologic oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$44,898
Medicare patients
85
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate12$218,776
EliquisApixaban17$11,403
Megestrol Acetate29$1,088
Prochlorperazine Maleate41$745
Ondansetron Hcl36$721
Tamoxifen Citrate24$666
Letrozole44$395
Lidocaine-PrilocaineLidocaine/Prilocaine20$249
Gabapentin26$205
Escitalopram Oxalate23$63
Oxycodone Hcl13$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$32$218,77612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 52 gynecologic oncology providers in North Carolina.

Other gynecologic oncology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →